Comparing Continuous and Intermittent Magnesium for Cancer Patients
Author Information
Author(s): E.E. Vokes, R. Mick, N.J. Vogelzang, R. Geiser, F. Douglas
Primary Institution: The University of Chicago Pritzker School of Medicine
Hypothesis
Can magnesium aspartate hydrochloride prevent or replenish magnesium loss in patients undergoing cisplatin chemotherapy?
Conclusion
The study found that continuous magnesium supplementation is more effective in preventing hypomagnesaemia in patients receiving cisplatin chemotherapy.
Supporting Evidence
- Patients receiving continuous magnesium had higher serum magnesium levels compared to those on intermittent therapy.
- By the third cycle of chemotherapy, nearly all patients in the intermittent group required magnesium supplementation.
- No patients experienced side effects related to magnesium administration.
- Severe hypomagnesaemia was rare in both treatment groups.
Takeaway
This study looked at how giving magnesium all the time versus only when needed helps cancer patients who are getting a specific type of chemotherapy. It turns out that giving it all the time is better.
Methodology
Patients were randomized into two groups: one received continuous magnesium supplementation, while the other received it only when magnesium levels dropped.
Potential Biases
No significant bias risks were reported.
Limitations
Some patients did not complete all cycles of therapy due to complications or personal choice.
Participant Demographics
Patients had locally advanced head and neck cancer and were previously untreated.
Statistical Information
P-Value
0.0004
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website